KR101974036B1 - 아연 핑거 모듈을 연결하기 위한 조성물 - Google Patents

아연 핑거 모듈을 연결하기 위한 조성물 Download PDF

Info

Publication number
KR101974036B1
KR101974036B1 KR1020187017770A KR20187017770A KR101974036B1 KR 101974036 B1 KR101974036 B1 KR 101974036B1 KR 1020187017770 A KR1020187017770 A KR 1020187017770A KR 20187017770 A KR20187017770 A KR 20187017770A KR 101974036 B1 KR101974036 B1 KR 101974036B1
Authority
KR
South Korea
Prior art keywords
artificial sequence
pro
seq
thr
description
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187017770A
Other languages
English (en)
Korean (ko)
Other versions
KR20180077284A (ko
Inventor
데이비드 파스촌
에드워드 제이. 레바르
Original Assignee
상가모 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상가모 테라퓨틱스, 인코포레이티드 filed Critical 상가모 테라퓨틱스, 인코포레이티드
Publication of KR20180077284A publication Critical patent/KR20180077284A/ko
Application granted granted Critical
Publication of KR101974036B1 publication Critical patent/KR101974036B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Contacts (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
KR1020187017770A 2010-05-03 2011-05-02 아연 핑거 모듈을 연결하기 위한 조성물 Active KR101974036B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34372910P 2010-05-03 2010-05-03
US61/343,729 2010-05-03
PCT/US2011/000758 WO2011139349A1 (en) 2010-05-03 2011-05-02 Compositions for linking zinc finger modules

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127028770A Division KR20130073887A (ko) 2010-05-03 2011-05-02 아연 핑거 모듈을 연결하기 위한 조성물

Publications (2)

Publication Number Publication Date
KR20180077284A KR20180077284A (ko) 2018-07-06
KR101974036B1 true KR101974036B1 (ko) 2019-04-30

Family

ID=44903931

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187017770A Active KR101974036B1 (ko) 2010-05-03 2011-05-02 아연 핑거 모듈을 연결하기 위한 조성물
KR1020127028770A Ceased KR20130073887A (ko) 2010-05-03 2011-05-02 아연 핑거 모듈을 연결하기 위한 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127028770A Ceased KR20130073887A (ko) 2010-05-03 2011-05-02 아연 핑거 모듈을 연결하기 위한 조성물

Country Status (18)

Country Link
US (2) US8772453B2 (enExample)
EP (2) EP2566972B1 (enExample)
JP (1) JP5898179B2 (enExample)
KR (2) KR101974036B1 (enExample)
CN (1) CN102959087B (enExample)
AU (1) AU2011249019B2 (enExample)
CA (1) CA2797189C (enExample)
CY (1) CY1122636T1 (enExample)
DK (1) DK2566972T3 (enExample)
ES (1) ES2773052T3 (enExample)
HR (1) HRP20200254T1 (enExample)
HU (1) HUE048072T2 (enExample)
IL (1) IL222632B (enExample)
LT (1) LT2566972T (enExample)
PL (1) PL2566972T3 (enExample)
PT (1) PT2566972T (enExample)
SI (1) SI2566972T1 (enExample)
WO (1) WO2011139349A1 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120196370A1 (en) 2010-12-03 2012-08-02 Fyodor Urnov Methods and compositions for targeted genomic deletion
EP2596011B1 (en) 2010-07-21 2018-10-03 Sangamo Therapeutics, Inc. Methods and compositions for modification of a hla locus
US9267123B2 (en) 2011-01-05 2016-02-23 Sangamo Biosciences, Inc. Methods and compositions for gene correction
EP2737063B1 (en) 2011-07-25 2016-06-01 Sangamo BioSciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
CA2852955C (en) 2011-10-27 2021-02-16 Sangamo Biosciences, Inc. Methods and compositions for modification of the hprt locus
US9528107B2 (en) * 2012-01-31 2016-12-27 Pacific Biosciences Of California, Inc. Compositions and methods for selection of nucleic acids
RU2639277C2 (ru) 2012-02-29 2017-12-20 Сангамо Байосайенсиз, Инк. Способы и составы лечения болезни хантингтона
JP6329537B2 (ja) 2012-07-11 2018-05-23 サンガモ セラピューティクス， インコーポレイテッド 生物学的薬剤の送達のための方法および組成物
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
CN104704110B (zh) 2012-08-29 2018-06-01 桑格摩生物科学股份有限公司 用于治疗遗传性病状的方法和组合物
US9290800B2 (en) 2013-03-15 2016-03-22 Pacific Biosciences Of California, Inc. Targeted rolling circle amplification
WO2014165612A2 (en) 2013-04-05 2014-10-09 Dow Agrosciences Llc Methods and compositions for integration of an exogenous sequence within the genome of plants
JP6588438B2 (ja) 2013-08-28 2019-10-09 サンガモ セラピューティクス， インコーポレイテッド Ｄｎａ結合ドメインと切断ドメインとを連結するための組成物
AU2014337248B2 (en) 2013-10-17 2020-09-24 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US10117899B2 (en) 2013-10-17 2018-11-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
EP3068905A4 (en) 2013-11-11 2017-07-05 Sangamo BioSciences, Inc. Methods and compositions for treating huntington's disease
PT3068881T (pt) 2013-11-13 2019-05-31 Childrens Medical Center Regulação da expressão de genes mediada por nucleases
US10072066B2 (en) 2014-02-03 2018-09-11 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a beta thalessemia
CA2942762C (en) 2014-03-18 2023-10-17 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
US10435685B2 (en) 2014-08-19 2019-10-08 Pacific Biosciences Of California, Inc. Compositions and methods for enrichment of nucleic acids
US10808020B2 (en) 2015-05-12 2020-10-20 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
WO2017011519A1 (en) 2015-07-13 2017-01-19 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
JP7128741B2 (ja) 2015-12-18 2022-08-31 サンガモ セラピューティクス， インコーポレイテッド Ｔ細胞受容体の標的化破壊
WO2017106537A2 (en) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the mhc cell receptor
WO2017123757A1 (en) 2016-01-15 2017-07-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
US10724020B2 (en) 2016-02-02 2020-07-28 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
MX2019002207A (es) 2016-08-24 2019-07-15 Sangamo Therapeutics Inc Regulacion de la expresion genica usando nucleasas modificadas.
ES2901989T3 (es) 2016-08-24 2022-03-24 Sangamo Therapeutics Inc Nucleasas específicas de objetivo modificadas
CA3039673A1 (en) 2016-10-20 2018-04-26 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
CA3041668A1 (en) 2016-10-31 2018-05-03 Sangamo Therapeutics, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
US11504389B2 (en) 2016-12-01 2022-11-22 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
TWI808079B (zh) 2017-04-03 2023-07-11 美商編碼製藥公司 組織選擇性轉基因表現
EP3615510B1 (en) 2017-04-28 2024-03-27 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11655275B2 (en) 2017-05-03 2023-05-23 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
BR112020002438A2 (pt) 2017-08-08 2020-07-28 Sangamo Therapeutics, Inc. direcionamento celular mediado por receptores de antígenos quiméricos
IL274323B2 (en) 2017-11-09 2024-10-01 Sangamo Therapeutics Inc Genetic modification of cytokine inducible sh2-containing protein (cish) gene
MA50942A (fr) 2017-12-01 2020-10-07 Encoded Therapeutics Inc Protéines de liaison à l'adn modifiées
CN111954540A (zh) 2018-02-08 2020-11-17 桑格摩生物治疗股份有限公司 工程化靶标特异性核酸酶
EP3781587A4 (en) * 2018-04-18 2022-03-30 Sangamo Therapeutics, Inc. ZINC FINGER PROTEIN COMPOSITIONS FOR THE MODULATION OF HUNTINGTINE (HTT)
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2020041249A1 (en) 2018-08-23 2020-02-27 Sangamo Therapeutics, Inc. Engineered target specific base editors
EP3853244A4 (en) 2018-09-18 2022-09-14 Sangamo Therapeutics, Inc. PROGRAMMED CELL DEATH 1 (PD1) SPECIFIC NUCLEASES
WO2020061426A2 (en) 2018-09-21 2020-03-26 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
US12318427B2 (en) 2018-10-02 2025-06-03 Sangamo Therapeutics, Inc. Methods and compositions for modulation of tau proteins
CA3115158A1 (en) * 2018-10-02 2020-04-09 Sangamo Therapeutics, Inc. Engineered genetic modulators
DK3908568T3 (da) 2019-01-11 2024-08-26 Acuitas Therapeutics Inc Lipider til lipidnanopartikellevering af aktivstoffer
EP3826664A4 (en) 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
WO2020205838A1 (en) 2019-04-02 2020-10-08 Sangamo Therapeutics, Inc. Methods for the treatment of beta-thalassemia
TW202521561A (zh) 2019-04-23 2025-06-01 美商聖加莫治療股份有限公司 染色體9開放讀框72基因表現之調節子及其用途
WO2020237045A1 (en) 2019-05-21 2020-11-26 Sangamo Therapeutics, Inc. Controlled transgene expression in regulatory t cells
EP3976798B1 (en) 2019-05-29 2025-12-17 Encoded Therapeutics, Inc. Compositions and methods for selective gene regulation
WO2021028359A1 (en) 2019-08-09 2021-02-18 Sangamo Therapeutics France Controlled expression of chimeric antigen receptors in t cells
AU2020356962A1 (en) 2019-10-02 2022-04-14 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for repressing alpha-synuclein expression
JP2022550608A (ja) 2019-10-02 2022-12-02 サンガモ セラピューティクス， インコーポレイテッド プリオン病の治療のためのジンクフィンガータンパク質転写因子
TW202130812A (zh) 2019-11-01 2021-08-16 美商聖加莫治療股份有限公司 用於基因體工程之組合物及方法
UY39036A (es) 2020-01-22 2021-08-31 Sangamo Therapeutics Inc Factores de transcripción de proteína de dedos de zinc para represión de la expresión tau
US20230174612A1 (en) * 2020-04-09 2023-06-08 The Regents Of The University Of California Notch receptors with zinc finger-containing transcriptional effector
US11976019B2 (en) 2020-07-16 2024-05-07 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
WO2022046760A2 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
KR20230074519A (ko) 2020-09-25 2023-05-30 상가모 테라퓨틱스, 인코포레이티드 핵염기 편집을 위한 아연 핑거 융합 단백질
AR123681A1 (es) 2020-10-02 2023-01-04 Sangamo Therapeutics Inc FACTORES DE TRANSCRIPCIÓN DE PROTEÍNAS DE DEDOS DE ZINC NOVEDOSOS PARA LA REPRESIÓN DE LA EXPRESIÓN DE a-SINUCLEÍNA
GB2619423A (en) 2020-12-22 2023-12-06 Chroma Medicine Inc Compositions and methods for epigenetic editing
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
KR20240123832A (ko) 2021-12-16 2024-08-14 아퀴타스 테라퓨틱스 인크. 지질 나노입자 제형에 사용하기 위한 지질
JP2025504606A (ja) 2021-12-22 2025-02-13 サンガモ セラピューティクス， インコーポレイテッド 核酸塩基編集のための新規ジンクフィンガー融合タンパク質
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
JP2025516294A (ja) 2022-05-01 2025-05-27 エヌクロマ・バイオ，インコーポレーテッド Ｐｃｓｋ９発現のエピジェネティック調節のための組成物及び方法
CA3260474A1 (en) 2022-06-23 2023-12-28 Chroma Medicine, Inc. COMPOSITIONS AND METHODS OF EPIGENETIC REGULATION OF B2M EXPRESSION
US20250387514A1 (en) 2022-06-23 2025-12-25 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of trac expression
EP4544058A1 (en) 2022-06-23 2025-04-30 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of ciita expression
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
AU2023347320A1 (en) 2022-09-23 2025-04-10 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2024081879A1 (en) 2022-10-14 2024-04-18 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of cd247 expression
WO2024238700A1 (en) 2023-05-15 2024-11-21 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053480A1 (en) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512110A (en) 1981-12-10 1985-04-23 Timesavers, Inc. Endless abrasive belts
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
CA2181548C (en) 1994-01-18 2009-11-03 Carlos F. Barbas, Iii Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
AU698152B2 (en) 1994-08-20 1998-10-22 Gendaq Limited Improvements in or relating to binding proteins for recognition of DNA
US7285416B2 (en) 2000-01-24 2007-10-23 Gendaq Limited Regulated gene expression in plants
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
DE69942334D1 (de) 1998-03-02 2010-06-17 Massachusetts Inst Technology Poly-zinkfinger-proteine mit verbesserten linkern
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US7151201B2 (en) 2000-01-21 2006-12-19 The Scripps Research Institute Methods and compositions to modulate expression in plants
WO2001059450A2 (en) 2000-02-08 2001-08-16 Sangamo Biosciences, Inc. Cells expressing zinc finger protein for drug discovery
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
US20060268407A1 (en) 2000-07-07 2006-11-30 Fergason James L Display system using two displays and polarization direction rotation for showing high-resolution and three-dimensional images and method and use of a DBEF beam splitter
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US20040197892A1 (en) * 2001-04-04 2004-10-07 Michael Moore Composition binding polypeptides
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
AU2003274404A1 (en) * 2002-06-11 2003-12-22 The Scripps Research Institute Artificial transcription factors
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
CA2539439C (en) 2003-09-19 2012-10-23 Sangamo Biosciences, Inc. Engineered zinc finger proteins for regulation of gene expression
KR20060123382A (ko) * 2003-12-23 2006-12-01 주식회사 툴젠 징크 핑거 단백질을 이용한 원핵세포의 유전자 발현 조절
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1737498A2 (en) 2004-04-08 2007-01-03 Sangamo Biosciences Inc. Zinc finger proteins for treatment of neuropathic pain
AU2005287278B2 (en) 2004-09-16 2011-08-04 Sangamo Biosciences, Inc. Compositions and methods for protein production
WO2006121866A2 (en) 2005-05-05 2006-11-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences
CN101273141B (zh) 2005-07-26 2013-03-27 桑格摩生物科学股份有限公司 外源核酸序列的靶向整合和表达
EP2628794B1 (en) 2005-10-18 2016-05-04 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
AU2007254251A1 (en) 2006-05-19 2007-11-29 Sangamo Therapeutics, Inc. Methods and compositions for inactivation of dihydrofolate reductase
AU2007267887B2 (en) 2006-05-25 2013-05-30 Sangamo Therapeutics, Inc. Variant Foki Cleavage Half-Domains
WO2007139982A2 (en) 2006-05-25 2007-12-06 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
CA2667414C (en) 2006-11-13 2015-12-29 Sangamo Biosciences, Inc. Methods and compositions for modification of the human glucocorticoid receptor locus
ATE489465T1 (de) 2007-04-26 2010-12-15 Sangamo Biosciences Inc Gezielte integration in die ppp1r12c-position
KR101657504B1 (ko) 2007-09-27 2016-09-19 상가모 바이오사이언스 인코포레이티드 생물학적으로 활성인 뉴클레아제의 신속한 생체내 확인
KR20120097483A (ko) 2009-07-24 2012-09-04 시그마-알드리치 컴퍼니., 엘엘씨 게놈 편집을 위한 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053480A1 (en) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules

Also Published As

Publication number Publication date
CA2797189C (en) 2020-05-26
ES2773052T3 (es) 2020-07-09
US8772453B2 (en) 2014-07-08
LT2566972T (lt) 2020-03-10
CY1122636T1 (el) 2021-03-12
EP2566972A4 (en) 2014-01-01
HUE048072T2 (hu) 2020-05-28
US20140287500A1 (en) 2014-09-25
PL2566972T3 (pl) 2020-06-29
EP2566972B1 (en) 2020-01-15
KR20130073887A (ko) 2013-07-03
AU2011249019B2 (en) 2015-01-22
DK2566972T3 (da) 2020-02-17
US20110287512A1 (en) 2011-11-24
IL222632A0 (en) 2012-12-31
HRP20200254T1 (hr) 2020-05-29
CN102959087B (zh) 2015-04-29
IL222632B (en) 2018-12-31
JP2013527765A (ja) 2013-07-04
KR20180077284A (ko) 2018-07-06
CN102959087A (zh) 2013-03-06
EP2566972A1 (en) 2013-03-13
US9163245B2 (en) 2015-10-20
EP3636766A1 (en) 2020-04-15
PT2566972T (pt) 2020-03-02
WO2011139349A1 (en) 2011-11-10
JP5898179B2 (ja) 2016-04-06
CA2797189A1 (en) 2011-11-10
SI2566972T1 (sl) 2020-04-30

Similar Documents

Publication Publication Date Title
KR101974036B1 (ko) 아연 핑거 모듈을 연결하기 위한 조성물
AU2011249019A1 (en) Compositions for linking zinc finger modules
US20240229079A9 (en) Engineered target specific nucleases
US10857203B2 (en) Methods and compositions for treating Huntington's disease
US10646543B2 (en) Methods and compositions for treating trinucleotide repeat disorders
US9522936B2 (en) Engineered transcription activator like effector (TALE) proteins
RU2693891C1 (ru) Способы и композиции для лечения болезни хантингтона
HK40026462A (en) Compositions for linking zinc finger modules
HK1182417B (en) Compositions for linking zinc finger modules
HK1182417A (en) Compositions for linking zinc finger modules
HK1193768A (en) Zinc finger fusion proteins for repressing a huntington gene
HK1193768B (en) Zinc finger fusion proteins for repressing a huntington gene

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7